요관경 검사 기기 시장 - 세계 예측(2026-2032년)

The Ureteroscopy Devices Market is projected to grow by USD 3.80 billion at a CAGR of 7.33% by 2032.

Ureteroscopy Devices Executive Summary

Ureteroscopy devices are central to contemporary endourology, enabling minimally invasive diagnosis and treatment of urinary tract stones, strictures, tumors, and upper tract abnormalities through direct visualization of the ureter and renal collecting system. The category includes rigid, semi-rigid, flexible, and single-use ureteroscopes, visualization systems, access sheaths, guidewires, stone retrieval baskets, laser fibers, irrigation systems, and ancillary instruments used in operating rooms and ambulatory surgical environments. Demand is shaped by the high clinical burden of urolithiasis, rising preference for organ-preserving and minimally invasive procedures, improved digital imaging, and broader availability of laser lithotripsy platforms. Clinical practice has increasingly moved toward smaller-diameter scopes, enhanced deflection, high-definition and digital chip-on-tip visualization, improved irrigation control, and infection-risk reduction through disposable or hybrid device strategies. Procurement decisions are influenced by durability, image quality, repair frequency, sterilization requirements, surgeon ergonomics, compatibility with lithotripsy energy sources, and total cost of procedure ownership. As health systems emphasize shorter hospital stays, lower complication rates, and faster patient recovery, ureteroscopy devices are positioned as essential tools in stone management and upper urinary tract intervention.

Transformative Shifts in the Ureteroscopy Device Landscape

The ureteroscopy devices landscape is being reshaped by the shift from conventional reusable optics toward digital flexible ureteroscopes, single-use endoscopes, and integrated endourology platforms. Hospitals are reassessing device portfolios as reprocessing complexity, scope repair costs, cross-contamination concerns, and procedure scheduling efficiency become more visible in clinical governance. Single-use ureteroscopes are gaining relevance in high-risk infection settings, emergency cases, and facilities with limited sterilization throughput, while reusable digital systems remain important for high-volume centers that can optimize maintenance and lifecycle management. Technology transformation is also visible in laser lithotripsy, where holmium:YAG systems remain widely used and thulium fiber laser adoption is increasing due to precise dusting capability, lower retropulsion, and potential efficiency benefits in stone fragmentation. Miniaturization is expanding access to challenging anatomy, and improvements in access sheaths, nitinol baskets, and hydrophilic guidewires are supporting safer navigation and stone retrieval. Sustainability has emerged as a balancing factor, with care providers evaluating the environmental implications of disposable scopes alongside infection prevention, logistics, and procedural consistency. Regulatory expectations for device traceability, sterilization validation, and clinical safety documentation are further reinforcing the need for evidence-based procurement and standardized endourology workflows.

Cumulative Impact of Artificial Intelligence on Ureteroscopy Devices

Artificial intelligence is beginning to influence ureteroscopy devices through image enhancement, workflow optimization, clinical decision support, training analytics, and procedural documentation. In endoscopic visualization, AI-enabled software can support real-time image clarification, stone boundary recognition, anatomy highlighting, and automated video analysis, although clinical deployment remains dependent on validation, regulatory clearance, and integration with operating room systems. AI also has practical value in preoperative planning by combining imaging, patient history, stone characteristics, and anatomical risk factors to support case selection, operative strategy, and instrument planning. In training environments, AI-assisted video review can help assess scope handling, laser safety, basket manipulation, mucosal trauma risk, and procedural efficiency, supporting competency-based education for urologists. Operationally, AI can analyze device utilization, repair histories, sterilization bottlenecks, and case scheduling patterns to improve inventory management and reduce downtime. The cumulative impact is not limited to robotics or automation; it is increasingly centered on creating a connected endourology ecosystem where data from imaging, devices, electronic records, and quality metrics improves safety, consistency, and resource allocation. Industry leaders should recognize that AI adoption will depend on transparent algorithms, interoperable data infrastructure, cybersecurity safeguards, and clinically meaningful outcomes rather than technology novelty alone.

Key Regional Insights Across Global Ureteroscopy Device Adoption

Asia-Pacific is advancing as a critical region for ureteroscopy devices due to rising kidney stone diagnoses, growing hospital infrastructure, expanding specialist training, and increasing access to endoscopic stone management in China, India, Japan, South Korea, Australia, and ASEAN countries. Regional demand is supported by dietary changes, urbanization, metabolic disease prevalence, climatic stone risk factors, and wider use of diagnostic imaging, while adoption patterns vary between tertiary urban hospitals and resource-constrained facilities. North America remains highly advanced in ureteroscopy practice, supported by strong endourology expertise, outpatient surgery utilization, reimbursement pathways for minimally invasive procedures, and broad availability of digital flexible scopes, laser lithotripsy, and infection-control protocols. Latin America is characterized by improving endoscopic urology capabilities in major urban centers, with Brazil and Mexico serving as important procedural hubs; however, access disparities, budget sensitivity, and public-sector procurement cycles influence device selection. Europe demonstrates mature clinical adoption, shaped by guideline-driven stone management, centralized procurement in many health systems, robust sterilization standards, and strong focus on patient safety, sustainability, and cost-effectiveness. The Middle East is seeing investment in advanced surgical infrastructure, particularly in high-income Gulf health systems where minimally invasive urology services are expanding alongside medical tourism and specialty care modernization. Africa presents a more heterogeneous environment, with growing need for kidney stone treatment but uneven access to endourology equipment, trained specialists, and maintenance support; opportunities are strongest where public-private investment, training partnerships, and durable device strategies address affordability and service continuity.

Key Group Insights for Ureteroscopy Device Strategy

ASEAN countries are increasingly prioritizing minimally invasive urology as healthcare systems expand specialist capacity, with adoption influenced by urban hospital investment, affordability requirements, tropical-climate stone burden, and demand for devices that can withstand high procedural throughput in mixed public-private settings. The GCC is distinguished by strong investment in hospital modernization, preference for advanced endoscopic systems, and emphasis on premium clinical infrastructure, making infection prevention, digital visualization, and integrated operating room compatibility important procurement drivers. The European Union reflects a highly regulated and standards-led environment in which ureteroscopy device adoption is shaped by clinical guidelines, medical device regulation, procurement transparency, reprocessing compliance, and growing sustainability scrutiny. BRICS countries represent a diverse but strategically important group where large patient populations, expanding diagnostic access, domestic manufacturing priorities, and increasing surgical capacity support broader ureteroscopy utilization, although reimbursement, local supply policy, and hospital resource variation affect adoption speed. G7 countries generally show mature uptake of flexible ureteroscopy, laser lithotripsy, ambulatory surgical pathways, and quality-driven procurement, with purchasing decisions often based on clinical evidence, lifecycle cost, device reliability, and infection-control performance. NATO countries span advanced and emerging healthcare systems, but defense-aligned supply chain resilience, cybersecurity expectations for connected devices, and hospital readiness standards are increasingly relevant as digital endoscopy platforms become more data-dependent and interoperable.

Key Country Insights in Ureteroscopy Device Utilization

The United States is a leading adopter of ureteroscopy devices, supported by high procedural volumes, outpatient surgical infrastructure, broad specialist availability, and strong emphasis on digital imaging, laser lithotripsy, and infection prevention. Canada shows consistent use of guideline-aligned stone management, with public healthcare procurement placing importance on clinical value, reprocessing capacity, and equitable access across provinces. Mexico is expanding endourology capabilities in major metropolitan hospitals, with demand influenced by private healthcare growth, rising imaging access, and the need for cost-effective systems. Brazil has a significant urology treatment base, and adoption is supported by tertiary care centers and specialist training, while public procurement constraints continue to shape device access. The United Kingdom emphasizes standardized clinical pathways, health technology assessment, and efficient use of operating theater resources, supporting evidence-based adoption of reusable and single-use ureteroscopy platforms where clinically justified. Germany benefits from advanced hospital infrastructure, strong surgical specialization, and high attention to engineering quality and sterilization performance. France combines guideline-based practice with public procurement discipline, while Russia's adoption is shaped by regional healthcare modernization, local supply considerations, and access differences between major centers and remote areas. Italy and Spain have mature endourology communities, with device decisions influenced by public hospital budgets, surgeon preference, and procedural efficiency. China is rapidly advancing in endoscopic urology through hospital expansion, domestic device development, and rising stone disease recognition. India has strong long-term need due to large patient volume, climatic and dietary stone risk factors, and expanding private hospital networks, while affordability and service reach remain central. Japan demonstrates high clinical sophistication, aging-population-related urology demand, and preference for precision instruments. Australia maintains advanced adoption supported by specialist centers and high standards for device safety. South Korea shows strong uptake of digital medical technologies, high hospital capability, and a competitive environment for minimally invasive urology innovation.

Actionable Recommendations for Ureteroscopy Device Industry Leaders

Industry leaders should prioritize evidence-driven product development focused on image quality, scope durability, ergonomic handling, deflection stability, irrigation performance, laser compatibility, and reduced infection risk. Product portfolios should address both reusable and single-use requirements, recognizing that hospitals increasingly compare total procedural value rather than acquisition cost alone. Manufacturers and distributors should strengthen clinical education programs covering safe access, laser settings, basket use, ureteral injury prevention, sterilization workflows, and post-procedure quality metrics. Supply chain strategies should include reliable availability of consumables such as guidewires, access sheaths, baskets, and laser fibers, since procedural continuity depends on complete system readiness. Stakeholders should invest in regulatory documentation, real-world evidence generation, and post-market surveillance to support trust among clinicians and procurement teams. Digital integration should be designed around interoperability, cybersecurity, and practical operating room usability, particularly as AI-enabled visualization and analytics become more relevant. Sustainability should be addressed through lifecycle assessment, responsible packaging, reprocessing efficiency, and transparent environmental claims. In emerging markets, success will depend on tiered offerings, serviceability, training partnerships, financing flexibility, and durable devices suited to local infrastructure conditions.

Research Methodology for Ureteroscopy Device Insights

This executive summary is developed through a structured secondary-research approach using verified clinical, regulatory, and industry-relevant sources, including urology guidelines, peer-reviewed medical literature, public health publications, medical device regulatory materials, hospital procurement considerations, and recognized clinical practice standards. The analysis focuses on qualitative market dynamics, technology evolution, regional adoption factors, healthcare infrastructure trends, and operational considerations in ureteroscopy device use. Information was evaluated for relevance to endourology practice, consistency across credible sources, and applicability to device strategy, procurement, and clinical implementation. The methodology excludes market sizing, market share estimation, and forecasting to maintain focus on evidence-backed insights and strategic interpretation. Key themes were synthesized across device categories, procedure settings, regional healthcare systems, and emerging technology areas such as digital endoscopy, single-use scopes, laser lithotripsy, infection prevention, and AI-enabled workflow support. Regional, group, and country insights were integrated into narrative form to support search visibility and provide decision-ready context for industry stakeholders.

Conclusion: Strategic Outlook for Ureteroscopy Devices

Ureteroscopy devices are evolving from standalone instruments into integrated, data-enabled endourology solutions that support safer, faster, and more consistent urinary stone and upper tract procedures. The market environment is being shaped by minimally invasive care pathways, digital visualization, single-use adoption, laser lithotripsy innovation, infection-control priorities, and growing interest in AI-supported clinical workflows. Regional dynamics differ significantly, with mature healthcare systems emphasizing clinical evidence, lifecycle cost, and procedural quality, while emerging systems focus on access, affordability, training, and infrastructure readiness. The strongest strategic opportunities will come from aligning device innovation with real-world clinical needs: reliable visualization, efficient stone clearance, reduced complications, streamlined reprocessing or disposal pathways, and measurable value for hospitals and patients. Organizations that combine robust technology, training, service support, regulatory discipline, and sustainable design will be best positioned to meet the expanding global need for effective ureteroscopy-based care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Ureteroscopy Devices Market, by Device Type

• 7.1. Introduction
• 7.2. Flexible Ureteroscopes
  • 7.2.1. Digital Flexible
  • 7.2.2. Fiber-Optic Flexible
• 7.3. Semi-Rigid Ureteroscopes

8. Ureteroscopy Devices Market, by Technology

• 8.1. Introduction
• 8.2. Digital Ureteroscopes
  • 8.2.1. Reusable
  • 8.2.2. Single Use
• 8.3. Fiber-Optic Ureteroscopes
  • 8.3.1. Reusable
  • 8.3.2. Single Use

9. Ureteroscopy Devices Market, by Accessories

• 9.1. Introduction
• 9.2. Laser Fibers
  • 9.2.1. Holmium Laser Fibers
  • 9.2.2. Thulium Laser Fibers
• 9.3. Stone Baskets
  • 9.3.1. Standard Baskets
  • 9.3.2. Tipless Baskets

10. Ureteroscopy Devices Market, by Application

• 10.1. Introduction
• 10.2. Diagnostic
  • 10.2.1. Inspection
  • 10.2.2. Visualization
• 10.3. Therapeutic
  • 10.3.1. Stone Management
    • 10.3.1.1. Basket Extraction
    • 10.3.1.2. Lithotripsy
  • 10.3.2. Tumor Management
    • 10.3.2.1. Biopsy
    • 10.3.2.2. Laser Ablation

11. Ureteroscopy Devices Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
  • 11.2.1. Freestanding
  • 11.2.2. Hospital Affiliated
• 11.3. Hospitals

12. Ureteroscopy Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Ureteroscopy Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Ureteroscopy Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Advin Health Care
• 16.2. Ambu A/S
• 16.3. Boston Scientific Corporation
• 16.4. Cliniva Healthcare
• 16.5. Coloplast A/S
• 16.6. ConMed Corporation
• 16.7. Cook Group Incorporated
• 16.8. Dornier MedTech
• 16.9. EMS Electro Medical Systems S.A.
• 16.10. Fujifilm Holdings Corporation
• 16.11. KARL STORZ SE & Co. KG
• 16.12. LocaMed Limited
• 16.13. Maxer Endoscopy GmbH
• 16.14. Medtronic plc
• 16.15. MicroPort Urocare
• 16.16. Olympus Corporation
• 16.17. OTU Medical
• 16.18. PENTAX Medical
• 16.19. Richard Wolf GmbH
• 16.20. ROCAMED
• 16.21. Stryker Corporation
• 16.22. Teleflex Incorporated
• 16.23. Vimex Endoscopy